BioMimetic Therapeutics, Inc. to Present at BIO CEO and Investor Conference

BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced today that Dr. Samuel E. Lynch, president and CEO, will provide an update of corporate activities at the 11^th Annual BIO CEO and Investor Conference on Tuesday, February 10 at 9:30 a.m. Eastern Time. The presentation is being held in the West Foyer at the Waldorf Astoria in New York City.

A live audio webcast of the presentation will be available at http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=BMTI&item_id=2077277 and on the Company’s website at www.biomimetics.com. The webcast will be accessible for a period of at least 30 days.

About BioMimetic Therapeutics

BioMimetic Therapeutics, Inc. is developing and commercializing bio-active recombinant protein-device combination products for the healing of musculoskeletal injuries and disease, including orthopedic, spine and sports injury applications. BioMimetic received marketing approval from the FDA for its first product, GEM 21S®, as a grafting material for bone and periodontal regeneration following completion of human clinical trials, which demonstrated the safety and efficacy of its platform technology in this indication. Additionally, the Company has clinical trials ongoing with its product candidates GEM OS1 and GEM OS2 in multiple orthopedic bone healing indications including the treatment of foot and ankle fusions and the stimulation of healing of fractures of the arm. The Company's previously approved product and lead product candidates all combine recombinant protein therapeutics with tissue specific scaffolds to actively stimulate tissue healing and regeneration.

GEM 21S® is a registered trademark of Luitpold Pharmaceuticals, Inc., who now owns and markets that product through its Osteohealth Company division.

For further information, visit www.biomimetics.com or contact Kearstin Patterson, corporate communications, at 615-236-4419.